Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 27, 2026

JPMorgan (JPM) Names Two Co Presidents As Jamie Dimon Succession Takes Shape

View original at finance.yahoo.com
JPMorgan (JPM) Names Two Co Presidents As Jamie Dimon Succession Takes Shape Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Succession specific factors, such as how Petno and Rohrbaugh manage capital allocation or compete with large peers like Bank of America and Citigroup, are not fully reflected in prior narrative commentary.

    60% confidence
  • Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

    60% confidence
  • That structure concentrates oversight of JPMorgan Chase's two largest engines at the same level as the CEO, which can help the board assess each candidate's readiness for the top role over time.

    60% confidence
  • Higher investment in talent retention and leadership reshaping could challenge earlier assumptions that spending would be contained, especially as the bank also invests in technology and branch expansion.

    60% confidence
  • JPMorgan Chase stock trades around $329.05, with a 1-year return of 16.8% and a 3-year return of 142.2%.

    60% confidence
  • Doug Petno now runs the Commercial & Investment Bank on his own, and Troy Rohrbaugh moves from markets into Consumer and Community Banking, with both serving as co-presidents.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
JPMorgan (JPM) Names Two Co Presidents As Jamie Dimon Succession Takes Shape — Source | Via News | Via News